SEC Filings

8-K

LORILLARD, INC. filed this Form 8-K on 06/27/2013

Entire Document

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K
CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 27, 2013

Lorillard, Inc.
(Exact name of registrant as specified in its charter)

DELAWARE
(State or other jurisdiction of incorporation)

001-34097
Commission File Number

13-1911176
(IRS Employer Identification No.)

714 Green Valley Road
Greensboro, North Carolina 27408-7018
(Address of principal executive offices, including zip code)

(336) 335-7000
Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

" Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

" Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

" Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

" Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LORILLARD, INC.
(Registrant)

By: /s/ David H. Taylor
David H. Taylor
Executive Vice President, Finance and Planning
and Chief Financial Officer

Dated: June 27, 2013

Exhibit 99.1
Kent Filter

- Alleged injury from asbestos in original Kent cigarette filter
  - Manufactured between 1952 and 1956
  - Claims usually involve mesothelioma
  - Smoking and health not an issue
- Worker claims from asbestos exposure in the plants
- Smoker claims
  - 60 pending suits
## Kent Filter (cont.)

- Verdicts in 22 cases tried since 1991 (17 defense verdicts; 5 plaintiff verdicts)
  - Damages ranged from $140,000 to $2.25 million
- Settlement strategy established to minimize economic loss
- Several trials scheduled for 2013